DGAP-News

Newron Pharmaceuticals unterstützt den Rare Disease Day(R) und schliesst sich der globalen Allianz zur Stärkung des Bewusstseins für seltene Krankheiten an - Seite 4

This document contains forward-looking statements, including (without
limitation) about (1) Newron's ability to develop and expand its business,
successfully complete development of its current product candidates and
current and future collaborations for the development and commercialisation
of its product candidates and reduce costs (including staff costs), (2) the
market for drugs to treat CNS diseases and pain conditions, (3) Newron's
anticipated future revenues, capital expenditures and financial resources,
and (4) assumptions underlying any such statements. In some cases these
statements and assumptions can be identified by the fact that they use
words such as "will", "anticipate", "estimate", "expect", "project",
"intend", "plan", "believe", "target", and other words and terms of similar
meaning. All statements, other than historical facts, contained herein
regarding Newron's strategy, goals, plans, future financial position,
projected revenues and costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent
risks and uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other outcomes described, assumed
or implied therein will not be achieved. Future events and actual results
could differ materially from those set out in, contemplated by or
underlying the forward-looking statements due to a number of important
factors. These factors include (without limitation) (1) uncertainties in
the discovery, development or marketing of products, including without
limitation negative results of clinical trials or research projects or
unexpected side effects, (2) delay or inability in obtaining regulatory
approvals or bringing products to market, (3) future market acceptance of
products, (4) loss of or inability to obtain adequate protection for
intellectual property rights, (5) inability to raise additional funds, (6)
success of existing and entry into future collaborations and licensing
agreements, (7) litigation, (8) loss of key executive or other employees,
(9) adverse publicity and news coverage, and (10) competition, regulatory,
legislative and judicial developments or changes in market and/or overall
economic conditions.

Newron may not actually achieve the plans, intentions or expectations
disclosed in forward-looking statements and assumptions underlying any such
statements may prove wrong. Investors should therefore not place undue
reliance on them. There can be no assurance that actual results of Newron's
research programmes, development activities, commercialisation plans,
collaborations and operations will not differ materially from the
expectations set out in such forward-looking statements or underlying
assumptions.
Newron does not undertake any obligation to publicly up-date or revise
forward looking statements except as may be required by applicable
regulations of the SIX Swiss Exchange where the shares of Newron are
listed.

This document does not contain or constitute an offer or invitation to
purchase or subscribe for any securities of Newron and no part of it shall
form the basis of or be relied upon in connection with any contract or
commitment whatsoever.


---------------------------------------------------------------------------

29.02.2016 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und http://www.dgap.de

---------------------------------------------------------------------------


440805 29.02.2016